Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia (Q33611942)

28 July 2017

1 reference

title

Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia (English)

1 reference

28 July 2017

M I Wilde

1 reference

28 July 2017

K L Goa

series ordinal

1 reference

28 July 2017

publication date

1 April 1999

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

28 July 2017

page(s)

557-581

1 reference

Medical management of benign prostatic hyperplasia other than with hormones or alpha blockers.

28 July 2017

cites work

1 reference

12 December 2020

Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group

1 reference

12 December 2020

Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia

1 reference

12 December 2020

Economic Burden of Treated Benign Prostatic Hyperplasia in the United Kingdom

1 reference

12 December 2020

Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride

1 reference

12 December 2020

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Stud

1 reference

12 December 2020

Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar

1 reference

12 December 2020

Differential suppression of serum prostatic acid phosphatase and prostate-specific antigen by 5-alpha-reductase inhibitor

1 reference

12 December 2020

Scandinavian Clinical Study of Finasteride in the Treatment of Benign Prostatic Hyperplasia

1 reference

12 December 2020

Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group

1 reference

12 December 2020

Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans

1 reference

12 December 2020

Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, i

1 reference

12 December 2020

Comparison of the cost-effectiveness of various therapies for common prostatic disorders

1 reference

12 December 2020

An economic evaluation of finasteride for treatment of benign prostatic hyperplasia

1 reference

12 December 2020

Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia

1 reference

12 December 2020

Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia

1 reference

12 December 2020

Qualitative and quantitative evaluation of prostatic histomorphology in rats following chronic treatment with finasteride, a 5-alpha reductase inhibitor

1 reference

12 December 2020

The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia

1 reference

12 December 2020

Benign prostatic hyperplasia. Current pharmacological treatment

1 reference

12 December 2020

Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-Extension Study. The Scandinavian Finasteride Study Group

1 reference

12 December 2020

Patient satisfaction with finasteride in the treatment of symptomatic benign prostatic hyperplasia

1 reference

12 December 2020

A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia

1 reference

12 December 2020

Effect of finasteride on free and total serum prostate-specific antigen in men with benign prostatic hyperplasia

1 reference

12 December 2020

Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score.

1 reference

12 December 2020

Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride. The Finasteride Study Group

1 reference

12 December 2020

Effects of Flutamide and Finasteride on Rat Testicular Descent

1 reference

12 December 2020

Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

12 December 2020

Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Finasteride Study Group

1 reference

12 December 2020

Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies

1 reference

12 December 2020

Economic issues and the management of benign prostatic hyperplasia

1 reference

12 December 2020

Urodynamic Effects of Finasteride in the Treatment of Bladder Outlet Obstruction due to Benign Prostatic Hyperplasia

1 reference

12 December 2020

Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia--a Clinical Research Center study.

1 reference

12 December 2020

Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients

1 reference

12 December 2020

Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate

1 reference

12 December 2020

The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy

1 reference

12 December 2020

New words for old: lower urinary tract symptoms for "prostatism"

1 reference

12 December 2020

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

12 December 2020

The development of human benign prostatic hyperplasia with age

1 reference

12 December 2020

Effect of finasteride on adrenal steroidogenesis in men

1 reference

12 December 2020

Evidence for atrophy and apoptosis in the prostates of men given finasteride

1 reference

12 December 2020

Reversible severe myopathy during treatment with finasteride

1 reference

12 December 2020

Prolonged treatment with finasteride (a 5α‐reductase inhibitor) does not affect bone density and metabolism

1 reference

12 December 2020

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

1 reference

12 December 2020

Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.

1 reference

12 December 2020

The effect of finasteride on prostate specific antigen: review of available data

1 reference

12 December 2020

Potential activities of androgen metabolizing enzymes in human prostate

1 reference

12 December 2020

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

12 December 2020

The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients.

1 reference

12 December 2020

Effect of 5-Alpha-Reductase Inhibition on Sex-Hormone-Binding Globulin in Elderly Men

1 reference

12 December 2020

Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting

1 reference

12 December 2020

Prostate-specific antigen: critical issues for the practicing physician

1 reference

12 December 2020

Alpha 1-blockers vs 5 alpha-reductase inhibitors in benign prostatic hyperplasia. A comparative review

1 reference

12 December 2020

Proscar: five-year experience.

1 reference

12 December 2020

Effect of finasteride on prostate-specific antigen density

1 reference

12 December 2020

Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia

1 reference

12 December 2020

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor

1 reference

12 December 2020

Finasteride, A Steroid 5α‐Reductase Inhibitor, Does Not Affect the Oxidative Metabolism of Antipyrine

1 reference

12 December 2020

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

12 December 2020

Critical developmental periods for effects on male rat genitalia induced by finasteride, a 5 alpha-reductase inhibitor.

1 reference

12 December 2020

The effect of a 5 alpha-reductase inhibitor on androgen physiology in the immature male rat

1 reference

12 December 2020

Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia

1 reference

12 December 2020

5 alpha-reductase inhibition by finasteride (Proscar) in epithelium and stroma of human benign prostatic hyperplasia

1 reference

12 December 2020

Gynecomastia and breast cancer during finasteride therapy

1 reference

12 December 2020

Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study

1 reference

12 December 2020

Finasteride: a slow-binding 5 alpha-reductase inhibitor.

1 reference

12 December 2020

Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients

1 reference

12 December 2020

Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study

1 reference

12 December 2020

Effects of long term treatment with finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating LH, FSH, prolactin and estradiol

1 reference

12 December 2020

Medical Treatment of Benign Prostatic Hyperplasia: 5α-Reductase Inhibitors and α-Adrenergic Antagonists

1 reference

12 December 2020

The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle

1 reference

12 December 2020

Urologists on a tightrope: coping with a changing economy.

1 reference

12 December 2020

Pharmacodynamic modeling of finasteride, a 5 alpha-reductase inhibitor

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of finasteride

1 reference

12 December 2020

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia

1 reference

12 December 2020

Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia

1 reference

12 December 2020

10.2165/00003495-199957040-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1043932529

0 references

1 reference